Thanks Eric
An eye-opening report. As with everything we do, appreciation of the clinical use of test results and potential impact on patients is critical. In my institution (tertiary oncology setting), the use of troponin testing is relatively low, therefore limiting the data available to assess lot-to-lot bias in this instance (my findings are mainly based on EQA results; ? matrix-issues).
We know that Troponin results are interpreted in the context of clinical symptoms of ischaemia, ECG changes, etc. Nonetheless, I have discussed this issue with the manufacturer and last week escalated to the MHRA (who have now asked Siemens to investigate), and logged internally via Medical Devices Committee for review.
Best wishes
Phil
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical community working in clinical biochemistry.
Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
Green Laboratories Work
http://www.laboratorymedicine.nhs.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|